NEW YORK (GenomeWeb) – Atlanta-based Cocrystal Pharma today announced licensing agreements with Duke University and Emory University for CRISPR/Cas9 technologies to be used in developing and commercializing antiviral therapeutics for hepatitis B virus (HBV) and human papilloma virus (HPV).
"We are excited to explore the CRISPR/Cas technologies to potentially develop the first virus-targeted genome-modifying treatment that may be able to provide a cure for HPV and HBV," Cocrystal CEO Jeffrey Meckler said in a statement.
Financial and other details of the agreements were not disclosed.
Cocrystal seeks to develop antiviral therapies for serious and chronic diseases. The firm said in a statement that it has identified compounds targeting hepatitis, influenza, and norovirus.
Editas Medicine has also licensed CRISPR-related technology developed at Duke.